Key result
Cancer survivors face ~37% higher heart failure risk, exposing major gaps in long-term prediction models.
Why the study?
Cancer survivors face an elevated risk of heart failure from prior cancer therapies and overlapping comorbidities, creating a growing need for heart failure specific risk prediction models to facilitate early diagnosis and timely management.
Do existing cardiovascular and cancer-specific risk prediction models accurately predict incident heart failure and cancer therapy-related cardiac dysfunction in patients with cancer and cancer survivors?
Do existing cardiovascular and cancer-specific risk prediction models accurately predict incident heart failure and cancer therapy-related cardiac dysfunction in patients with cancer and cancer survivors?
This review summarizes current heart failure risk prediction models for cancer patients and survivors, highlighting the transition from general cardiovascular calculators to cancer-specific tools and the ongoing need for long-term survivorship prediction models.
Answers are grounded in this paper and cite their sources.
Current models miss long-term HF risk in cancer survivors; leaves open development of validated prediction tools beyond peri-treatment periods.
Purpose of Review: Cancer survivors have an elevated risk for developing heart failure due to prior chemotherapy, radiation therapy, and other overlapping co-morbid conditions. With the advancement in cancer treatment, there is an increasing number of survivors who are at an even higher risk of developing heart failure. There is a growing need for heart failure specific risk prediction models in this population to facilitate early diagnosis and timely management. This review aims to summarize most recent findings on heart failure risk prediction among patients with history of cancer. Recent findings: Current risk prediction models focus on heart failure risk at the time of cancer treatment and shortly thereafter. There is limited data on heart failure risk among long term survivors. Graphical Abstract Central Figure: Approach in determining heart failure risk before, during, and, after cancer treatment
No takes yet. Share an insight, caveat, or question.
Agdamag et al. (2026) conducted a review in Heart failure in patients with cancer and cancer survivors. Cardiotoxic cancer therapies and heart failure risk prediction models was evaluated on Incident heart failure and cancer therapy-related cardiac dysfunction. Cancer survivors face an elevated risk of heart failure (HR 1.37, 95% CI 1.26-1.50), yet current risk prediction models primarily assess short-term treatment toxicity rather than long-term risk.
Synapse has enriched 10 related papers. Consider them for comparative context: